Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece

Nes-Ziona, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the ...

READ THE ORIGINAL POST AT nz.finance.yahoo.com